ONCY — ONCOLYTICS BIOTECH INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1129928 ·
Last close
$0.68
Market Cap
$86.71M
52W High
$1.51
52W Low
$0.64
ADV30
953,330
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -9,379,000 | -9,442,000 | 7,671,000 | 4,115,000 | 13,838,000 |
| Mar 2026 | 0 | — | -9,281,000 | -9,243,000 | 8,161,000 | 5,493,000 | 13,291,000 |
| Dec 2025 | 0 | — | -9,651,891 | -9,177,897 | 7,582,000 | 5,202,000 | 11,381,000 |
| Sep 2025 | 0 | — | -9,944,315 | -10,346,686 | 10,818,753 | 8,875,157 | 10,736,124 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,672,000
Investing CF
$-11,000
Financing CF
$17,551,000
CapEx
$-13,970
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-438,738,000
Inventory
—
Receivables
$961,000
ST Investments
—
EBIT TTM
$-33,047,191
Pretax Income TTM
$-33,192,965
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,725,000 | -28,759,000 | 7,582,000 | 11,381,000 | -3,799,000 | -20,112,000 |
| Dec 2024 | 0 | -25,542,000 | -22,794,000 | 13,421,000 | 10,123,000 | 3,298,000 | -19,883,000 |
| Dec 2023 | 0 | -25,471,883 | -20,919,644 | 29,262,777 | 8,485,602 | 20,777,175 | -21,444,294 |
| Dec 2022 | 0 | -19,837,902 | -18,298,703 | 27,508,105 | 7,981,138 | 19,526,967 | -17,208,223 |
TTM Snapshot
Revenues TTM
$117,000
NetIncome TTM
$-4,711,000
OpCashFlow TTM
$0
Assets (Latest)
$7,582,000
Forward EPS
$-0.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $87.61M | $0.76 | — |
| RLYB | Rallybio Corp | $88.26M | $16.62 | — |
| RACC | Research Alliance Corp III | $84.90M | $10.92 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $84.59M | $1.23 | — |
News headlines (Yahoo Finance, 1h cache)
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC
2026-08-27 10:10 · Yahoo
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials
2026-08-19 06:15 · Yahoo
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)
2026-07-13 14:13 · Yahoo
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics
2026-06-16 16:42 · Yahoo
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention
2026-06-04 06:11 · Yahoo
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial
2026-07-16 11:16 · Yahoo
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
2026-06-01 15:26 · Yahoo
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
2026-09-28 13:30 · Yahoo
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
2026-09-28 12:00 · Yahoo
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
2026-09-16 02:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.